Sheaffer, A.K., Mulherin, H.M., Chen, C., Dunaj, C.V., Lee, M.S., Franco, D.L., Campbell, J., Sit, S. Characterization of HCVreplicons resistant to inhibitors of NS3 protease activity. Proceedings of the 7th International Symposiu. 2004. . . Find at Google Scholar.
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inh. Gastroenterology. 2007. 132(5). . Find at Google Scholar.
Zeuzem S, Sarrarin C, Rouzier R, Tarral A, Brion N, Forestier N, Gupta S, Deckman D, Fellows K, Huss. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in HCV-1 pa. Hepatology. 2005. 42(1). 233A. Find at Google Scholar.
Zeuzem S, Sarrarin C, Wagner F, Rouzier R, Forestier N, Gupta S, Hussain M, Shah A, Cutler D, Zhang . Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-intron in hepatitis C genotype-. Hepatology. 2005. 42(1). 276A. Find at Google Scholar.
Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. . Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SC. Antiviral Res. . 2006. 70(2). 28-38. Find at Google Scholar.
Tong X, Guo Z, Wright-Minogue J, Xia E, Prongay A, Madison V, Qiu P, Venkatraman S, Velazquez F, Njo. Impact of naturally occurring variants of HCV protease on the binding of different classes of protea. Biochemistry. 2006. 45(5). 1353-1361. Find at Google Scholar.
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inh. Gastroenterology. 2007. 132(5). . Find at Google Scholar.
Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia. Characterization of resistance mutations against HCV ketoamide protease inhibitors.. Antiviral Res.. 2008. 77(3). 177-185. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receivi. PLoS One. 2012. 7(4). e34372. Find at Google Scholar.
Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: re. Gastroenterology. 2011. 140(3). 755-760. Find at Google Scholar.
Curry S, Qiu P, Tong X. . Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir a. J Virol Methods. 2008. 153(2). 156-162. Find at Google Scholar.
Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann . Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected pa. Hepatology. 2009. 50(6). 1709-1718. Find at Google Scholar.
Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009. 49(4). 1069-1082. Find at Google Scholar.
Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. . Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibito. Antimicrob Agents Chemother. . 2010. 54(12). 5288-5297. Find at Google Scholar.